Rassy Elie El, Bakouny Ziad, Aoun Fouad, Haddad Fadi G, Sleilaty Ghassan, Assi Tarek, Kattan Joseph
Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Department of Urology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Immunotherapy. 2018 Jun;10(8):657-663. doi: 10.2217/imt-2017-0190. Epub 2018 Mar 22.
To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer.
METHODS & MATERIALS: Only the pivotal Phase III trials of second-line metastatic urothelial bladder cancer were included in this network meta-analysis.
This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pembrolizumab was the only treatment with positive effect on overall survival compared with the best supportive care. The treatment discontinuation rates due to adverse events of the pembrolizumab and atezolizumab did not differ from that of the best supportive care. C onclusion: Our results confirmed the superiority of pembrolizumab in the management of metastatic urothelial bladder cancer.
确定哪种已获批的免疫检查点抑制剂是转移性尿路上皮膀胱癌的最佳治疗方法。
本网络荟萃分析仅纳入了二线转移性尿路上皮膀胱癌的关键III期试验。
该网络荟萃分析纳入了三项汇总试验（NCT00315237、NCT02256436和NCT02302807），共1125名参与者。与最佳支持治疗相比，帕博利珠单抗是唯一对总生存期有积极影响的治疗方法。帕博利珠单抗和阿特珠单抗因不良事件导致的治疗中断率与最佳支持治疗的无差异。结论：我们的结果证实了帕博利珠单抗在转移性尿路上皮膀胱癌治疗中的优越性。
